Restricted accessResearch articleFirst published online 2019-2
Extracellular Vesicles from Wharton's Jelly Mesenchymal Stem Cells Suppress CD4 Expressing T Cells Through Transforming Growth Factor Beta and Adenosine Signaling in a Canine Model
Mesenchymal stem cells (MSCs) are widely investigated as potential therapeutic agents due to their potent immunomodulatory capacity. Although specific mechanisms by which MSC acts on immune cells are emerging, many questions remain, including the potential of extracellular vesicles (EVs) to mediate biological activities. Canine MSCs are of interest for both veterinary and comparative models of disease and have been shown to suppress CD4pos T cell proliferation. The aim of this study was to determine whether EV isolated from canine Wharton's jelly-derived MSC (WJ-MSC EV) suppresses CD4pos T cell proliferation using biochemical mechanisms previously ascribed to soluble mediators [transforming growth factor beta (TGF-β) and adenosine]. WJ-MSC EV exhibited mode of 125 nm diameter, low buoyant density (1.1 g/mL), and expression of EV proteins Alix and TSG101. Functionally, EVs inhibited CD4pos T cell proliferation in a dose-dependent manner, which was absent in EV-depleted samples and EVs from non-MSC fibroblasts. EV suppression of CD4pos T cell proliferation was inhibited by a TGF-βRI antagonist, neutralizing antibodies to TGF-β, or A2A adenosine receptor blockade. TGF-β was present on EVs as latent complexes most likely tethered to EV membrane by betaglycan. These data demonstrate that canine WJ-MSC EV utilizes TGF-β and adenosine signaling to suppress proliferation of CD4pos T cell and will enable further investigation into mechanisms of immune cell modulation, as well as refinement of WJ-MSC and their EVs for therapeutic application.
Get full access to this article
View all access options for this article.
References
1.
CanA, CelikkanFT and CinarO. (2017). Umbilical cord mesenchymal stromal cell transplantations: a systemic analysis of clinical trials. Cytotherapy, 19:1351–1382.
2.
Joerger-MesserliMS, MarxC, OppligerB, MuellerM, SurbekDV and SchoeberleinA. (2016). Mesenchymal stem cells from wharton's jelly and amniotic fluid. Best Pract Res Clin Obstet Gynaecol, 31:30–44.
3.
El OmarR, BeroudJ, StoltzJF, MenuP, VelotE and DecotV. (2014). Umbilical cord mesenchymal stem cells: the new gold standard for mesenchymal stem cell-based therapies?. Tissue Eng Part B Rev, 20:523–544.
4.
RizkM, AzizJ, ShorrR and AllanDS. (2017). Cell-based therapy using umbilical cord blood for novel indications in regenerative therapy and immune modulation: an updated systematic scoping review of the literature. Biol Blood Marrow Transplant, 23:1607–1613.
5.
DaviesJE, WalkerJT and KeatingA. (2017). Concise review: Wharton's Jelly: the rich, but enigmatic, source of mesenchymal stromal cells. Stem Cells Transl Med, 6:1620–1630.
6.
DondersR, BogieJFJ, RavanidisS, GervoisP, VanheusdenM, MaréeR, SchrynemackersM, SmeetsHJM, PinxterenJ, et al. (2018). Human Wharton's jelly-derived stem cells display a distinct immunomodulatory and proregenerative transcriptional signature compared to bone marrow-derived stem cells. Stem Cells Dev, 27:65–84.
7.
WangQ, YangQ, WangZ, TongH, MaL, ZhangY, ShanF, MengY and YuanZ. (2016). Comparative analysis of human mesenchymal stem cells from fetal-bone marrow, adipose tissue, and Warton's jelly as sources of cell immunomodulatory therapy. Hum Vaccin Immunother, 12:85–96.
8.
LiX, BaiJ, JiX, LiR, XuanY and WangY. (2014). Comprehensive characterization of four different populations of human mesenchymal stem cells as regards their immune properties, proliferation and differentiation. Int J Mol Med, 34:695–704.
9.
YooKH, JangIK, LeeMW, KimHE, YangMS, EomY, LeeJE, KimYJ, YangSK, et al. (2009). Comparison of immunomodulatory properties of mesenchymal stem cells derived from adult human tissues. Cell Immunol, 259:150–156.
10.
HeH, Nagamura-InoueT, TakahashiA, MoriY, YamamotoY, ShimazuT, TsunodaH and TojoA. (2015). Immunosuppressive properties of Wharton's jelly-derived mesenchymal stromal cells in vitro. Int J Hematol, 102:368–378.
11.
WeissML, AndersonC, MedicettyS, SeshareddyKB, WeissRJ, VanderWerffI, TroyerD and McIntoshKR. (2008). Immune properties of human umbilical cord Wharton's jelly-derived cells. Stem Cells, 26:2865–2874.
12.
SaulnierN, LoriauJ, FebreM, RobertC, RakicR, BonteT, BuffS and MaddensS. (2016). Canine placenta: a promising potential source of highly proliferative and immunomodulatory mesenchymal stromal cells?. Vet Immunol Immunopathol, 171:47–55.
13.
BarciaRN, SantosJM, FilipeM, TeixeiraM, MartinsJP, AlmeidaJ, Agua-DoceA, AlmeidaSC, VarelaA, et al. (2015). What makes umbilical cord tissue-derived mesenchymal stromal cells superior immunomodulators when compared to bone marrow derived mesenchymal stromal cells?. Stem Cells Int, 2015:583984.
14.
RibeiroA, LaranjeiraP, MendesS, VeladaI, LeiteC, AndradeP, SantosF, HenriquesA, GrãosM, et al. (2013). Mesenchymal stem cells from umbilical cord matrix, adipose tissue and bone marrow exhibit different capability to suppress peripheral blood B, natural killer and T cells. Stem Cell Res Ther, 4:125.
15.
PoltavtsevAM, PoltavtsevaRA, YushinaMN, PavlovichSV and SvirshchevskayaEV. (2017). Proliferation of peripheral blood lymphocytes and mesenchymal stromal cells derived from Wharton's jelly in mixed and membrane-separated cultures. Bull Exp Biol Med, 163:542–549.
16.
NajarM, RaicevicG, BoufkerHI, Fayyad KazanH, De BruynC, MeulemanN, BronD, ToungouzM and LagneauxL. (2010). Mesenchymal stromal cells use PGE2 to modulate activation and proliferation of lymphocyte subsets: combined comparison of adipose tissue, Wharton's jelly and bone marrow sources. Cell Immunol, 264:171–179.
17.
PachlerK, KetterlN, DesgeorgesA, DunaiZA, Laner-PlambergerS, StreifD, StrunkD, RohdeE and GimonaM. (2017). An in vitro potency assay for monitoring the immunomodulatory potential of stromal cell-derived extracellular vesicles. Int J Mol Sci, 18:E1413.
18.
ZhangB, YinY, LaiRC, TanSS, ChooAB and LimSK. (2014). Mesenchymal stem cells secrete immunologically active exosomes. Stem Cells Dev, 23:1233–1244.
19.
WillisGR, Fernandez-GonzalezA, AnastasJ, VitaliSH, LiuX, EricssonM, KwongA, MitsialisSA and KourembanasS. (2018). Mesenchymal stromal cell exosomes ameliorate experimental bronchopulmonary dysplasia and restore lung function through macrophage immunomodulation. Am J Respir Crit Care Med, 197:104–116.
20.
LiW, ZhangQ, WangM, WuH, MaoF, ZhangB, JiR, GaoS, SunZ, et al. (2013). Macrophages are involved in the protective role of human umbilical cord-derived stromal cells in renal ischemia-reperfusion injury. Stem Cell Res, 10:405–416.
21.
SongJY, KangHJ, HongJS, KimCJ, ShimJY, LeeCW and ChoiJ. (2017). Umbilical cord-derived mesenchymal stem cell extracts reduce colitis in mice by re-polarizing intestinal macrophages. Sci Rep, 7:9412.
22.
PhinneyDG and PittengerMF. (2017). Concise review: MSC-derived exosomes for cell-free therapy. Stem Cells, 35:851–858.
23.
YañezR, LamanaML, García-CastroJ, ColmeneroI, RamírezM and BuerenJA. (2006). Adipose tissue-derived mesenchymal stem cells have in vivo immunosuppressive properties applicable for the control of the graft-versus-host disease. Stem Cells, 24:2582–2591.
24.
KourembanasS. (2015). Exosomes: vehicles of intercellular signaling, biomarkers, and vectors of cell therapy. Annu Rev Physiol, 77:13–27.
25.
ReinerAT, WitwerKW, van BalkomBWM, de BeerJ, BrodieC, CortelingRL, GabrielssonS, GimonaM, IbrahimAG, et al. (2017). Concise review: developing best-practice models for the therapeutic use of extracellular vesicles. Stem Cells Transl Med, 6:1730–1739.
26.
MatthayMA. (2017). Extracellular vesicle transfer from mesenchymal stromal cells modulates macrophage function in acute lung injury. Basic science and clinical implications. Am J Respir Crit Care Med, 196:1234–1236.
BörgerV, BremerM, Ferrer-TurR, GockelnL, StambouliO, BecicA and GiebelB. (2017). Mesenchymal stem/stromal cell-derived extracellular vesicles and their potential as novel immunomodulatory therapeutic agents. Int J Mol Sci, 18:E1450.
29.
BrunoS, DeregibusMC and CamussiG. (2015). The secretome of mesenchymal stromal cells: role of extracellular vesicles in immunomodulation. Immunol Lett, 168:154–158.
30.
ZhangB, YinY, LaiRC and LimSK. (2014). Immunotherapeutic potential of extracellular vesicles. Front Immunol, 5:518.
31.
Lo SiccoC, ReverberiD, BalbiC, UliviV, PrincipiE, PascucciL, BecheriniP, BoscoMC, VaresioL, et al. (2017). Mesenchymal stem cell-derived extracellular vesicles as mediators of anti-inflammatory effects: endorsement of macrophage polarization. Stem Cells Transl Med, 6:1018–1028.
32.
KordelasL, RebmannV, LudwigAK, RadtkeS, RuesingJ, DoeppnerTR, EppleM, HornPA, BeelenDW and GiebelB. (2014). MSC-derived exosomes: a novel tool to treat therapy-refractory graft-versus-host disease. Leukemia, 28:970–973.
33.
Monguió-TortajadaM, RouraS, Gálvez-MontónC, PujalJM, AranG, SanjurjoL, FranquesaM, SarriasMR, Bayes-GenisA and BorràsFE. (2017). Nanosized UCMSC-derived extracellular vesicles but not conditioned medium exclusively inhibit the inflammatory response of stimulated T cells: implications for nanomedicine. Theranostics, 7:270–284.
34.
WillisGR, MitsialisSA and KourembanasS. (2018). “Good things come in small packages”: application of exosome-based therapeutics in neonatal lung injury. Pediatr Res, 83:298–307.
35.
Gouveia de AndradeAV, BertolinoG, RiewaldtJ, BiebackK, KarbanováJ, OdendahlM, BornhäuserM, SchmitzM, CorbeilD and TonnT. (2015). Extracellular vesicles secreted by bone marrow- and adipose tissue-derived mesenchymal stromal cells fail to suppress lymphocyte proliferation. Stem Cells Dev, 24:1374–1376.
36.
ChengA, SN and I Colmegna(2017). Soluble factors, not extracellular vesicles, are key determinants of MSC: T cell suppression. J Extracell Vesicles, 6:ISEV2017.
37.
MatulaZ, NémethA, L̶rinczP, SzepesiÁ, BrózikA, BuzásEI, L̶wP, NémetK, UherF and UrbánVS. (2016). The role of extracellular vesicle and tunneling nanotube-mediated intercellular cross-talk between mesenchymal stem cells and human peripheral T cells. Stem Cells Dev, 25:1818–1832.
38.
Di TrapaniM, BassiG, MidoloM, GattiA, KamgaPT, CassaroA, CarusoneR, AdamoA and KramperaM. (2016). Differential and transferable modulatory effects of mesenchymal stromal cell-derived extracellular vesicles on T, B and NK cell functions. Sci Rep, 6:24120.
39.
LudwigS, FlorosT, TheodorakiMN, HongCS, JacksonEK, LangS and WhitesideTL. (2017). Suppression of lymphocyte functions by plasma exosomes correlates with disease activity in patients with head and neck cancer. Clin Cancer Res, 23:4843–4854.
40.
WhitesideTL. (2017). Exosomes carrying immunoinhibitory proteins and their role in cancer. Clin Exp Immunol, 189:259–267.
41.
HongCS, FunkS, MullerL, BoyiadzisM and WhitesideTL. (2016). Isolation of biologically active and morphologically intact exosomes from plasma of patients with cancer. J Extracell Vesicles, 5:29289.
42.
MullerL, MitsuhashiM, SimmsP, GoodingWE and WhitesideTL. (2016). Tumor-derived exosomes regulate expression of immune function-related genes in human T cell subsets. Sci Rep, 6:20254.
43.
HongCS, MullerL, WhitesideTL and BoyiadzisM. (2014). Plasma exosomes as markers of therapeutic response in patients with acute myeloid leukemia. Front Immunol, 5:160.
44.
TroyerRM, RubyCE, GoodallCP, YangL, MaierCS, AlbarqiHA, BradyJV, BathkeK, TaratulaO, MourichD and BrachaS. (2017). Exosomes from osteosarcoma and normal osteoblast differ in proteomic cargo and immunomodulatory effects on T cells. Exp Cell Res, 358:369–376.
45.
ClaytonA, MitchellJP, CourtJ, MasonMD and TabiZ. (2007). Human tumor-derived exosomes selectively impair lymphocyte responses to interleukin-2. Cancer Res, 67:7458–7466.
46.
BurrelloJ, MonticoneS, GaiC, GomezY, KholiaS and CamussiG. (2016). Stem cell-derived extracellular vesicles and immune-modulation. Front Cell Dev Biol, 4:83.
47.
MokarizadehA, DelirezhN, MorshediA, MosayebiG, FarshidAA and Dalir-NaghadehB. (2012). Phenotypic modulation of auto-reactive cells by insertion of tolerogenic molecules via MSC-derived exosomes. Vet Res Forum, 3:257–261.
48.
MokarizadehA, DelirezhN, MorshediA, MosayebiG, FarshidAA and MardaniK. (2012). Microvesicles derived from mesenchymal stem cells: potent organelles for induction of tolerogenic signaling. Immunol Lett, 147:47–54.
49.
FavaroE, CarpanettoA, LamorteS, FuscoA, CaorsiC, DeregibusMC, BrunoS, AmorosoA, GiovarelliM, et al. (2014). Human mesenchymal stem cell-derived microvesicles modulate T cell response to islet antigen glutamic acid decarboxylase in patients with type 1 diabetes. Diabetologia, 57:1664–1673.
50.
Del FattoreA, LucianoR, PascucciL, GoffredoBM, GiordaE, ScapaticciM, FierabracciA and MuracaM. (2015). Immunoregulatory effects of mesenchymal stem cell-derived extracellular vesicles on T lymphocytes. Cell Transplant, 24:2615–2627.
51.
HoffmanAM and DowSW. (2016). Concise review: stem cell trials using companion animal disease models. Stem Cells, 34:1709–1729.
52.
KolA, ArziB, AthanasiouKA, FarmerDL, NoltaJA, RebhunRB, ChenX, GriffithsLG, VerstraeteFJ, MurphyCJ and BorjessonDL. (2015). Companion animals: translational scientist's new best friends. Sci Transl Med, 7:308ps21.
53.
ChowL, JohnsonV, CoyJ, ReganD and DowS. (2017). Mechanisms of immune suppression utilized by canine adipose and bone marrow-derived mesenchymal stem cells. Stem Cells Dev, 26:374–389.
LeeKS, NahJJ, LeeBC, LeeHT, LeeHS, SoBJ and ChaSH. (2013). Maintenance and characterization of multipotent mesenchymal stem cells isolated from canine umbilical cord matrix by collagenase digestion. Res Vet Sci, 94:144–151.
56.
KhatriM, O'BrienTD and SharmaJM. (2009). Isolation and differentiation of chicken mesenchymal stem cells from bone marrow. Stem Cells Dev, 18:1485–1492.
57.
LaiRC, ChenTS and LimSK. (2011). Mesenchymal stem cell exosome: a novel stem cell-based therapy for cardiovascular disease. Regen Med, 6:481–492.
58.
GuoBB, BellinghamSA and HillAF. (2015). The neutral sphingomyelinase pathway regulates packaging of the prion protein into exosomes. J Biol Chem, 290:3455–3467.
59.
HasanM, NeumannB, HaupeltshoferS, StahlkeS, FantiniMC, AngstwurmK, BogdahnU and KleiterI. (2015). Activation of TGF-beta-induced non-Smad signaling pathways during Th17 differentiation. Immunol Cell Biol, 93:662–672.
60.
WebberJP, SparyLK, SandersAJ, ChowdhuryR, JiangWG, SteadmanR, WymantJ, JonesAT, KynastonH, et al. (2015). Differentiation of tumour-promoting stromal myofibroblasts by cancer exosomes. Oncogene, 34:290–302.
61.
ZabeoD, CvjetkovicA, LässerC, SchorbM, LötvallJ and HöögJL. (2017). Exosomes purified from a single cell type have diverse morphology. J Extracell Vesicles, 6:1329476.
62.
PoulosJ. (2018). The limited application of stem cells in medicine: a review. Stem Cell Res Ther, 9:1.
63.
SeoMS, ParkSB and KangKS. (2012). Isolation and characterization of canine Wharton's jelly-derived mesenchymal stem cells. Cell Transplant, 21:1493–1502.
64.
KramperaM, GalipeauJ, ShiY, TarteK, SensebeL and MSC Committee of the International Society for Cellular Therapy (ISCT). (2013). Immunological characterization of multipotent mesenchymal stromal cells-The International Society for Cellular Therapy (ISCT) working proposal. Cytotherapy, 15:1054–1061.
65.
Filioli UranioM, Dell'AquilaME, CairaM, GuaricciAC, VenturaM, CatacchioCR, MartinoNA and ValentiniL. (2014). Characterization and in vitro differentiation potency of early-passage canine amnion- and umbilical cord-derived mesenchymal stem cells as related to gestational age. Mol Reprod Dev, 81:539–551.
66.
TakemitsuH, ZhaoD, YamamotoI, HaradaY, MichishitaM and AraiT. (2012). Comparison of bone marrow and adipose tissue-derived canine mesenchymal stem cells. BMC Vet Res, 8:150.
67.
de BakkerE, Van RyssenB, De SchauwerC and MeyerE. (2013). Canine mesenchymal stem cells: state of the art, perspectives as therapy for dogs and as a model for man. Vet Q, 33:225–233.
68.
DominiciM, Le BlancK, MuellerI, Slaper-CortenbachI, MariniF, KrauseD, DeansR, KeatingA, ProckopDj and HorwitzE. (2006). Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy, 8:315–317.
69.
WillisGR, KourembanasS and MitsialisSA. (2017). Toward exosome-based therapeutics: isolation, heterogeneity, and fit-for-purpose potency. Front Cardiovasc Med, 4:63.
70.
LötvallJ, HillAF, HochbergF, BuzásEI, Di VizioD, GardinerC, GhoYS, IV, KurochkinIV, MathivananS, et al. (2014). Minimal experimental requirements for definition of extracellular vesicles and their functions: a position statement from the International Society for Extracellular Vesicles. J Extracell Vesicles, 3:26913.
71.
HosseinikiaR, NikbakhtMR, MoghaddamAA, TajehmiriA, HosseinikiaM, OubariF, Nikougoftar ZarifM, PasdarY and MansouriK. (2017). Molecular and cellular interactions of allogenic and autologus mesenchymal stem cells with innate and acquired immunity and their role in regenerative medicine. Int J Hematol Oncol Stem Cell Res, 11:63–77.
72.
BarciaRN, SantosJM, TeixeiraM, FilipeM, PereiraARS, MinistroA, Agua-DoceA, CarvalheiroM, GasparMM, et al. (2017). Umbilical cord tissue-derived mesenchymal stromal cells maintain immunomodulatory and angiogenic potencies after cryopreservation and subsequent thawing. Cytotherapy, 19:360–370.
73.
ClarkKC, KolA, ShahbenderianS, GranickJL, WalkerNJ and BorjessonDL. (2016). Canine and equine mesenchymal stem cells grown in serum free media have altered immunophenotype. Stem Cell Rev, 12:245–256.
74.
YuL, YangF, JiangL, ChenY, WangK, XuF, WeiY, CaoX, WangJ and CaiZ. (2013). Exosomes with membrane-associated TGF-beta1 from gene-modified dendritic cells inhibit murine EAE independently of MHC restriction. Eur J Immunol, 43:2461–2472.
75.
WebberJ, SteadmanR, MasonMD, TabiZ and ClaytonA. (2010). Cancer exosomes trigger fibroblast to myofibroblast differentiation. Cancer Res, 70:9621–9630.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
